EXACT Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

EXACT Therapeutics şirketinin toplam hissedar öz sermayesi NOK17.4M ve toplam borcu NOK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NOK31.4M ve NOK13.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NOK 0

Borç

Faiz karşılama oranı	n/a
Nakit	NOK 15.80m
Eşitlik	NOK 17.44m
Toplam yükümlülükler	NOK 13.92m
Toplam varlıklar	NOK 31.36m

Son finansal sağlık güncellemeleri

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Aug 09

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

Apr 20

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Sep 07

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

May 06

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Dec 30

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Jan 31

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Aug 21

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

May 21

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EXTX 'nin kısa vadeli varlıkları ( NOK26.8M ) kısa vadeli yükümlülüklerini ( NOK13.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: EXTX şirketinin kısa vadeli varlıkları ( NOK26.8M ) uzun vadeli yükümlülüklerini ( NOK653.7K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EXTX borçsuzdur.

Borcun Azaltılması: EXTX şirketinin 5 yıl önce borç/öz sermaye oranı 0.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EXTX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: EXTX un, serbest nakit akışı her yıl % 8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

EXACT Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer Trial

New major risk - Share price stability

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

New minor risk - Financial data availability

New minor risk - Share price stability

EXACT Therapeutics AS to Report Fiscal Year 2023 Results on Apr 18, 2024

New minor risk - Shareholder dilution

Chair of the Board recently sold kr300k worth of stock

EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.

EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023

EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study

EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study

No independent directors

EXACT Therapeutics AS Announces Management Changes

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

No independent directors

Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial

No independent directors

EXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

No independent directors

Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy

No independent directors

No independent directors

EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

No independent directors

EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022

No independent directors

EXACT Therapeutics as Announces Board Changes

No independent directors

EXACT Therapeutics AS Announces Resignation of Dr. Jean-Claude Provost as Board Member

No independent directors

EXACT Therapeutics AS Appoints Per Walday as Chief Executive Officer

EXACT Therapeutics AS Announces Clinical Trial Update

No independent directors

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Executive Chairperson recently bought kr71k worth of stock

Director Hans Klouman has left the company

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Deputy Chairperson recently bought kr208k worth of stock

EXACT Therapeutics AS Announces Clinical Trial Update

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

Chief Financial Officer has left the company

EXACT Therapeutics AS Announces Executive Changes

Exact Therapeutics Announces Innovative Probe Development Collaboration with GE Healthcare

New 90-day low: kr25.50

New 90-day low: kr31.50

EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million.

EXACT Therapeutics AS to Report Fiscal Year 2019 Results on Apr 29, 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin